Journal article
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC
E Samuel, G Lie, A Balasubramanian, A Hiong, Y So, M Voskoboynik, M Moore, M Shackleton, A Haydon, T John, PLR Mitchell, B Markman, P Briggs, S Parakh
Clinical Lung Cancer | CIG MEDIA GROUP, LP | Published : 2021
Abstract
Background: The impact of radiotherapy (RT) on the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in patients with metastatic non–small-cell lung cancer (NSCLC) is unclear. Materials and Methods: We identified patients with metastatic NSCLC treated with the anti-programmed death 1 antibodies nivolumab or pembrolizumab between January 2016 and May 2019 at 3 tertiary centers, who were also treated with palliative RT either during or within 3 months of starting anti-programmed death 1 treatment. Patient demographics, tumor characteristics, and treatment history were collected. Response rates, progression-free survival (PFS), and overall survival (OS) were analyzed and correlated w..
View full abstract